SIGN UP

September 30, 2016 11:19 AM EDT

Week in review: Clinton over Trump; the hubs have it; we'll always have Paris

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

TRENDING NOW

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

GSK awaits Nucala decision after FDA target date passes

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

AstraZeneca loses appeals court fight over IRA drug price negotiations

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges